Giulio Superti-Furga, Dr.

17.5.1962
born in Milano, Italy

Functions

Member of University Council 2013/14–2014/15

Current Position (July 2017)

Scientific Director and CEO of CeMM, Guest Professor of Molecular Pharmacology Med Univ Vienna

Scientific Education and Career History

1968-1981: German School of Milan
1981-1986: Diploma studies of Molecular Biology, University of Zurich (M. Busslinger, M.L. Birnstiel)
1987-1991: Ph.D. studies at University of Zurich, Genentech, Inc, and I.M.P. Vienna. Degree in Molecular Biology University of Zurich (M. Busslinger, M.L. Birnstiel)
1991-1993: Postdoctoral fellow European Molecular Biology Laboratory, Heidelberg (G. Draetta, S. Courtneidge)
1993-2004: Staff Scientist and Team Leader European Moelcular Biology Laboratory
1997-2000: Adj. Professor of Molecular Biology at the University of Bologna
2000-2005: Founder and Scientific Director Cellzome AG and Inc., Heidelberg
2005-present: Guest Professor of Molecular Pharmacology, Medical University of Vienna
2005-present: Scientific Director CeMM

Other Functions

Chair, EMBL Alumni Association
Member of the Standing Technical Evaluation Committee of the Lombardy Region for Research Funds
Member of the Harvard Armenise Foundation Fellowship Committee (until 2012)
Chair of the Committees awarding the FEBS Letters Young Group Leader Prize (until 2011)
Chair af the John Kendrew Award of the EMBL Alumni Association
Member of the Ignaz L. Lieben Prize Committee
Member of the Jubiläumsfonds der Stadt Wien
Member of non-partisan "Österreich 2025" Think-Tank (section "Innovationsland Österreich")

Scientific Advisory Board Member (selection)

IARC (International Agency for Cancer Research, Lyon, France)
EAB Board Member Institute for Research in Biomedicine (IRB Barcelona)
HSR San Raffaele (Milan)
Cellzome Inc. (Heidelberg and Cambridge)
Helmholtz Alliance on Systems Biology (Germany)
Virtual Liver Network (largest Systems Biology in Europe, German Ministry)
Austrian Association of Molecular Life Sciences and Biotechnology
SAB Expert Proteomics Panel Roche
Evaluation Board Chair VIB Ghent

Zuletzt aktualisiert am 03/07/24